牛牛AI助手已提取核心信息
Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, has filed a prospectus related to an amended and restated sales agreement with TD Cowen, under which the company may offer and sell shares of its common stock up to an aggregate offering price of $100,000,000. The common stock is listed on the Nasdaq Global Select Market under the symbol 'ARQT.' The sales are to be made in 'at-the-market' equity offerings as defined by Rule 415(a)(4) under the Securities Act of 1933. TD Cowen will act as the sales agent and will receive up to 3.0% of the aggregate gross proceeds from any sales made under the agreement. The company plans to use the net proceeds for general corporate purposes and to fund the continued development and commercialization of its product candidates. The prospectus was dated February 8, 2024, and the last reported sale price of Arcutis' common stock on January 30, 2024, was $5.87 per share.
Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, has filed a prospectus related to an amended and restated sales agreement with TD Cowen, under which the company may offer and sell shares of its common stock up to an aggregate offering price of $100,000,000. The common stock is listed on the Nasdaq Global Select Market under the symbol 'ARQT.' The sales are to be made in 'at-the-market' equity offerings as defined by Rule 415(a)(4) under the Securities Act of 1933. TD Cowen will act as the sales agent and will receive up to 3.0% of the aggregate gross proceeds from any sales made under the agreement. The company plans to use the net proceeds for general corporate purposes and to fund the continued development and commercialization of its product candidates. The prospectus was dated February 8, 2024, and the last reported sale price of Arcutis' common stock on January 30, 2024, was $5.87 per share.
处于商业阶段的生物制药公司Arcutis Biotherapeutics, Inc. 已提交了一份与经修订和重述的TD Cowen销售协议相关的招股说明书，根据该协议，该公司可以发行和出售其普通股，总发行价不超过1亿美元。普通股在纳斯达克全球精选市场上市，股票代码为 “ARQT”。根据1933年《证券法》第415（a）（4）条的定义，销售将以 “在场” 股票发行中进行。TD Cowen将担任销售代理，最多可获得协议下任何销售总收益的3.0％。该公司计划将净收益用于一般公司用途，并为其候选产品的持续开发和商业化提供资金。招股说明书的日期为2024年2月8日，Arcutis普通股最后一次公布的销售价格为每股5.87美元。
处于商业阶段的生物制药公司Arcutis Biotherapeutics, Inc. 已提交了一份与经修订和重述的TD Cowen销售协议相关的招股说明书，根据该协议，该公司可以发行和出售其普通股，总发行价不超过1亿美元。普通股在纳斯达克全球精选市场上市，股票代码为 “ARQT”。根据1933年《证券法》第415（a）（4）条的定义，销售将以 “在场” 股票发行中进行。TD Cowen将担任销售代理，最多可获得协议下任何销售总收益的3.0％。该公司计划将净收益用于一般公司用途，并为其候选产品的持续开发和商业化提供资金。招股说明书的日期为2024年2月8日，Arcutis普通股最后一次公布的销售价格为每股5.87美元。
有用
没用